Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015, Article ID 373490, 4 pages
http://dx.doi.org/10.1155/2015/373490
Case Report

JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis?

Department of Hematology, Institute of Liver and Biliary Sciences, New Delhi 110070, India

Received 5 February 2015; Revised 12 March 2015; Accepted 12 March 2015

Academic Editor: Ramon Tiu

Copyright © 2015 Pratibha Dhiman and Priyanka Saxena. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. P. Donadini, F. Dentali, and W. Ageno, “Splanchnic vein thrombosis: new risk factors and management,” Thrombosis Research, vol. 129, no. 1, pp. S93–S96, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Martinelli, M. Franchini, and P. M. Mannucci, “How I treat rare venous thromboses,” Blood, vol. 112, no. 13, pp. 4818–4823, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Sazawal, S. Rathi, S. Chikkara et al., “JAK2 mutation in patients with splanchnic venous thrombosis: a pilot study from India,” Indian Journal of Medical Research, vol. 135, no. 3, pp. 429–431, 2012. View at Google Scholar · View at Scopus
  4. D. Colaizzo, L. Amitrano, G. L. Tiscia et al., “The JAK2V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis,” Journal of Thrombosis and Haemostasis, vol. 5, no. 1, pp. 55–61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. P. D. Ziakas, “Effect of JAK2V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain,” Haematologica, vol. 93, no. 9, pp. 1412–1414, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. L. Levine, M. Wadleigh, J. Cools et al., “Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis,” Cancer Cell, vol. 7, no. 4, pp. 387–397, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. V. De Stefano, A. Fiorini, E. Rossi et al., “Incidence of the JAK2V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders,” Journal of Thrombosis and Haemostasis, vol. 5, no. 4, pp. 708–714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Primignani, G. Barosi, G. Bergamaschi et al., “Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis,” Hepatology, vol. 44, no. 6, pp. 1528–1534, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. P. J. Campbell, L. M. Scott, G. Buck et al., “Definition of subtypes of essential thrombocythemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study,” The Lancet, vol. 366, no. 9501, pp. 1945–1953, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Finazzi, A. Rambaldi, V. Guerini, A. Carobbo, and T. Barbui, “Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2V617F mutation status,” Haematologica, vol. 92, no. 1, pp. 135–136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. A. M. Vannucchi, E. Antonioli, P. Guglielmelli et al., “Clinical profile of homozygous JAK2617V>F mutation in patients with polycythemia vera or essential thrombocythemia,” Blood, vol. 110, no. 3, pp. 840–846, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. P. Wolanskyj, T. L. Lasho, S. M. Schwager et al., “JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance,” British Journal of Haematology, vol. 131, no. 2, pp. 208–213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. B. L. Stein, A. Rademaker, J. L. Spivak, and A. R. Moliterno, “Gender and vascular complications in the JAK2V617F-positive myeloproliferative neoplasms,” Thrombosis, vol. 2011, Article ID 874146, 8 pages, 2011. View at Publisher · View at Google Scholar
  14. G. Rotunno, C. Mannarelli, P. Guglielmelli et al., “Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia,” Blood, vol. 123, no. 10, pp. 1552–1555, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Haslam and S. E. Langabeer, “Incidence of CALR mutations in patients with splanchnic vein thrombosis,” British Journal of Haematology, vol. 168, no. 3, pp. 459–460, 2015. View at Publisher · View at Google Scholar
  16. A. G. Fleischman and J. W. Tyner, “Causal role for JAK2V617F in thrombosis,” Blood, vol. 122, no. 23, pp. 3705–3706, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Sokolowska, A. Nowaczyńska, K. Bykowska et al., “JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients,” Folia Histochemica et Cytobiologica, vol. 49, no. 2, pp. 267–271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. H. J. M. Brinkman, K. Mertens, and J. A. van Mourik, “Proteolytic cleavage of protein S during the hemostatic response,” Journal of Thrombosis and Haemostasis, vol. 3, no. 12, pp. 2712–2720, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Dienava-Verdoold, M. R. Marchetti, L. C. J. te Boome et al., “Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies,” Thrombosis and Haemostasis, vol. 107, no. 3, pp. 468–476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. P. D. Valle, L. Crippa, A. M. Garlando et al., “Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in antiphospholipid-antibody syndrome,” Haematologica, vol. 84, no. 12, pp. 1065–1074, 1999. View at Google Scholar · View at Scopus